App-Quantinova.ai

Baseline high-sensitivity C-reactive protein to predict progression-free survival in metastatic renal cell carcinoma patients treated with first-line sunitinib.

Ryuichi Mizuno - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

ILS-969

Highly sensitive C reactive protein (hsCRP) as a surrogate marker of head and neck cancer.

Preethi Bangalore Lakshmangowda - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma of the head and neck

N/A

Macrophage inhibitory cytokine 1 plasma levels in testicular cancer patients during cisplatin combination treatment and their relation to endothelial damage.

Renske Altena - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Testicular cancer

Etoposide

ELEVATED LIPOPROTEIN(A) AND HS-CRP AS A POOR PROGNOSTIC MARKER IN PATIENTS WITH CORONARY ARTERY DISEASE

Y. Yoon - European Atherosclerosis Society (EAS) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

EFFECT OF ETHANOLIC FRACTION OF TERMINALIA ARJUNA ON INFLAMMATORY MARKERS IN HYPERCHOLESTEROLEMIC RABBITS

V. Dhawan - European Atherosclerosis Society (EAS) , 2015

Therapeutic Area

Disease

Drug/Treatment

N/A

Atorvastatin

POLYSACCHARIDE PEPTIDE (PSP) EXHIBITS ANTI-ATHEROSCLEROTIC EFFECT THROUGH REGULATION OF LOCAL INFLAMMATORY RESPONSE IN ATHEROSCLEROSIS

S. Reverentia - European Atherosclerosis Society (EAS) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

Interleukin-10

DIMINISHED FREQUENCY OF CD4+IL10+ T-LYMPHOCYTES PREDICTS CORONARY ATHEROSCLEROSIS PROGRESSION

A. Potekhina - European Atherosclerosis Society (EAS) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

Interleukin-10

POLYMORPHISMS IN SOCS 1 AND 3 AND HUMAN CORONARY ARTERY DISEASE

J. Marti-Jaun - European Atherosclerosis Society (EAS) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

HDL-C IS AN INDEPENDENT PREDICTOR OF IL-6 AND SVCAM-1 CONCENTRATIONS

W.N.H. Wan Ahmad - European Atherosclerosis Society (EAS) , 2015

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Hypertension

sICAM-1

BIOMARKERS OF ATHEROSCLEROTIC PLAQUES INSTABILITY. RESULTS OF ARTERIAL WALL AND BLOOD STUDIES

A. Chernjavskiy - European Atherosclerosis Society (EAS) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Vasodilation dysfunction

endothelin-1

CLINICAL IMPACT OF NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN AND MATRIX METALLOPEPTIDASE-9 LEVEL ACCORDING TO PLAQUE MORPHOLOGICAL CHARACTERISTICS ASSESSED BY OPTICAL COHERENCE TOMOGRAPHY IN ACUTE CORONARY SYNDROME PATIENTS

H. Joo - European Atherosclerosis Society (EAS) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute Coronary Syndromes

Mofezolac

ENHANCED INFLAMMATION AND ENDOTHELIAL ACTIVATION IN CENTRAL OBESITY AND METABOLIC SYNDROME IRRESPECTIVE OF GLYCEMIC STATUS

H. Saimin - European Atherosclerosis Society (EAS) , 2015

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Metabolic syndrome

ILS-969

INFLAMMATION AND OXIDATIVE STRESS BIOMARKERS AS PREDICTORS OF DIASTOLIC DYSFUNCTION IN PATIENTS WITH METABOLIC SYNDROME

R. Rahaian - European Atherosclerosis Society (EAS) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Diastolic dysfunction

glutathione

INTENSIVE DOSE OF ROSUVASTATIN (40 MG/DAY), INITIATED EARLY AND CONTINUED FOR 12 WEEKS, IN VERY HIGH-RISK OR HIGH-RISK INDIAN PATIENTS

C. Shah - European Atherosclerosis Society (EAS) , 2015

Therapeutic Area

Disease

Drug/Treatment

N/A

Rosuvastatin

COMPLEMENTARY EFFECT OF COMBINATION OF STATINS WITH COENZYME Q10 AND OMEGA-3 FATTY ACIDS IN PATIENTS WITH COMBINED DYSLIPIDEMIA

M. Sajty - European Atherosclerosis Society (EAS) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Dyslipidemia

Coenzyme Q10

ASSESSMENT OF HIGH SENSITIVITY C-REACTIVE PROTEIN IN ETT POSITIVE PATIENTS WITH NORMAL CORONARY ANGIOGRAM.

S. Haque - European Atherosclerosis Society (EAS) , 2015

Therapeutic Area

Disease

Drug/Treatment

N/A

Familial Hyperaldosteronism Type I, Early Diagnosis and Treatment: Avoiding Future Complications

Carolina Mendoza - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Glucocorticoid remediable aldosteronism

Glucocorticoid

FSH Levels Predict Ongoing Bone Loss in Premenopausal Women Treated for Breast Cancer More Than a Year after Treatment

Laila Shaheen Tabatabai - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Premature ovarian failure

Alora

FSH Levels Predict Ongoing Bone Loss in Premenopausal Women Treated for Breast Cancer More Than a Year after Treatment

Laila Shaheen Tabatabai - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Premature ovarian failure

Alora

Vitamin-D Supplementation in Prediabetes Reduced Progression to type2 Diabetes through Decreased Insulin Resistance and Systemic Inflammation: An Open Label Randomized Prospective Study from Eastern India

Deep Dutta - Endocrine Society (ENDO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Prediabetes

cholecalciferol

Filters

1408 Abstracts